{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-061028","form_type":"8-K","ticker":"NEUP","cik":"0001191070","company_name":"Neuphoria Therapeutics Inc.","filed_at":"2026-05-26T20:15:40+00:00","discovered_at":"2026-05-26T20:18:01.515648+00:00","generated_at":"2026-05-26T20:33:27.755080+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"confidence":"high","headline":"Neuphoria receives AUD 1.416M CTx CRC payment; eligible for ~4.65% of $460M milestones","bullets":["Received AUD 1.416M from CTx CRC upon Pfizer's Phase III start in ER+/HER2- metastatic breast cancer.","Believes eligible for ~4.65% of future milestone payments from CTXT, total estimated at USD 460M across all parties.","Total distributions received from CTx CRC since 2016: AUD 3.52M.","Historical licensing revenues include AUD 967K from MSD (PRMT5) in 2016 and multiple Pfizer-related payments.","Company is a passive party and cannot determine whether future milestones will be achieved or payment amounts."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-061028","json":"https://secwatch.observer/filing/0001213900-26-061028.json","markdown":"https://secwatch.observer/filing/0001213900-26-061028.md","text":"https://secwatch.observer/filing/0001213900-26-061028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1191070/000121390026061028/0001213900-26-061028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1191070/000121390026061028/ea0292160-8k_neuphoria.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T20:33:27.755080+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}